Article Information
PubMed
Published By
History
- Received January 23, 2020
- Returned for modification March 7, 2020
- Accepted March 17, 2020
- Published online May 21, 2020.
Copyright & Usage
Copyright © 2020 Gebremariam et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Article Versions
- Accepted Manuscript version (March 23, 2020).
- You are viewing the most recent version of this article.
Author Information
- Teclegiorgis Gebremariama,
- Sondus Alkhazrajia,
- Abdullah Alqarihia,
- Nathan P. Wiederholdb,
- Karen Joy Shawc,
- Thomas F. Pattersonb,d,
- Scott G. Fillera,e and
- Ashraf S. Ibrahima,e
- aThe Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA
- bUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
- cHearts Consulting Group, San Diego, California, USA
- dSouth Texas Veterans Health Care System, San Antonio, Texas, USA
- eDavid Geffen School of Medicine at UCLA, Los Angeles, California, USA
- Address correspondence to Karen Joy Shaw, kshaw{at}amplyx.com, or Ashraf S. Ibrahim, ibrahim{at}lundquist.org.
Citation Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Shaw KJ, Patterson TF, Filler SG, Ibrahim AS. 2020. Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to Rhizopus arrhizus. Antimicrob Agents Chemother 64:e00178-20. https://doi.org/10.1128/AAC.00178-20.